CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Results of operations · Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- 4 Planned sale President and CEO sold 15,200 shares at $3.47 ($52,753)
- 4 Planned sale Chief Legal Officer & Corp Sec sold 8,933 shares at $3.48 ($31,048)
- 4 Planned sale CFO & Chief Business Officer sold 4,242 shares at $3.71 ($15,717)
- 4 Planned sale Chief Medical Officer sold 3,124 shares at $3.71 ($11,604)
- 4 Planned sale Chief Operating Officer sold 2,833 shares at $3.73 ($10,555)
Page 10 of 19 · 365 filings